{"id":32645,"date":"2026-08-27T11:17:30","date_gmt":"2026-08-27T09:17:30","guid":{"rendered":"https:\/\/cancerprev.com\/?page_id=32645"},"modified":"2026-08-27T11:17:53","modified_gmt":"2026-08-27T09:17:53","slug":"medicine-society-the-human-condition-2027","status":"publish","type":"page","link":"https:\/\/cancerprev.com\/de\/medicine-society-the-human-condition-2027\/","title":{"rendered":"Medicine & Society: The human condition 2027"},"content":{"rendered":"
\"\"<\/figure>\n\n\n\n

Registration below<\/a><\/p>\n\n\n\n

\"\"<\/span>
\n

Speakers 2027<\/p>\n\n\n\n

\"\"<\/figure>
\n

PROF. DOUGLAS HANAHAN<\/strong><\/p>\n\n\n\n

“TBA”<\/p>\n\n\n\n

Distinguished Scholar and Interim Director, Ludwig Institute for Cancer Research, Lausanne Branch<\/em><\/p>\n\n\n\n

January 21st 2027, 4PM (CET)<\/p>\n<\/div><\/div>\n\n\n\n

Douglas Hanahan is a world-renowned cancer biologist whose research has transformed our understanding of how tumors develop and progress. He is particularly known for developing pioneering mouse models of cancer and for his influential work on tumor angiogenesis, the tumor microenvironment, and mechanisms of therapeutic resistance. Together with Robert Weinberg, he authored the landmark Hallmarks of Cancer<\/em> framework, which has profoundly shaped modern cancer research. He is an elected member of the US National Academy of Sciences and the National Academy of Medicine, as well as a Foreign Member of the Royal Society.<\/p>\n\n\n\n

\n\n\n\n
\"\"<\/figure>
\n

PROF. REBECCA FITZGERALD<\/strong><\/p>\n\n\n\n

“TBA”

Professor of Cancer Prevention and Head of the Department of Oncology, University of Cambridge; Director, Early Cancer Institute<\/em><\/p>\n\n\n\n

February 18th 2027, 4PM (CEST)<\/p>\n<\/div><\/div>\n\n\n\n

Rebecca Fitzgerald is a physician-scientist and internationally recognised leader in the early detection and prevention of cancer. Her research focuses particularly on oesophageal cancer and Barrett\u2019s oesophagus, combining molecular biology, clinical studies, and innovative diagnostic technologies.<\/p>\n\n\n\n

She led the development of the Cytosponge\u2122, a minimally invasive test designed to improve the detection of Barrett\u2019s oesophagus and early oesophageal cancer. She is an Honorary Consultant in Gastroenterology at Addenbrooke\u2019s Hospital and was elected a Fellow of the Royal Society in 2024.<\/p>\n\n\n\n

\n\n\n\n
\"\"<\/figure>
\n

PROF. MICHAEL KARIN<\/strong><\/p>\n\n\n\n

“Inflammation, Obesity and Cancer; From Virchow to to the Curse of Plenty”<\/p>\n\n\n\n

Distinguished Professor of Pharmacology and Pathology, University of California San Diego<\/em><\/em><\/p>\n\n\n\n

March 18th 2027, 4PM (CEST)<\/p>\n<\/div><\/div>\n\n\n\n

Michael Karin is an internationally renowned scientist whose work has uncovered fundamental mechanisms linking inflammation, immunity, metabolism, and cancer. His research has identified key stress- and inflammation-responsive signalling pathways and helped establish how chronic inflammation can promote tumor development and progression.<\/p>\n\n\n\n

His current research addresses inflammatory signalling, innate immunity, metabolic disease, and cancer, with particular interests in liver and pancreatic tumorigenesis. He is an elected member of the US National Academy of Sciences and National Academy of Medicine and has received numerous international awards for his contributions to cancer and inflammation research.<\/p>\n\n\n\n

\n\n\n\n
\"\"<\/figure>
\n

PROF. CONNIE CEPKO<\/strong><\/p>\n\n\n\n

“TBA”<\/p>\n\n\n\n

Bullard Professor of Genetics and Neuroscience, Harvard Medical School; Howard Hughes Medical Institute Investigator<\/em><\/p>\n\n\n\n

May 13th 2027, 4PM (CEST)<\/p>\n<\/div><\/div>\n\n\n\n

Connie Cepko is a leading geneticist and neuroscientist whose research has provided fundamental insights into the development and function of the nervous system, particularly the retina. Her laboratory uses molecular, genetic, and cellular approaches to understand how different neuronal cell types are generated and how their identities are established.<\/p>\n\n\n\n

Her research also addresses retinal degeneration and the development of gene-based strategies to preserve vision in inherited forms of blindness. She is an elected member of the US National Academy of Sciences and the American Academy of Arts and Sciences.<\/p>\n\n\n\n

\n\n\n\n
\"\"<\/figure>
\n

PROF. FIONA WATT<\/strong><\/p>\n\n\n\n

“TBA”<\/p>\n\n\n\n

Director, European Molecular Biology Organization (EMBO); Group Leader, EMBL Heidelberg; Professor, King\u2019s College London<\/em><\/p>\n\n\n\n

June 17th 2027, 4PM (CEST)<\/p>\n<\/div><\/div>\n\n\n\n

Fiona Watt is a leading stem cell biologist whose research has transformed our understanding of how adult tissues are maintained and regenerated. Her work focuses particularly on the mechanisms controlling epidermal stem cell fate, differentiation, and tissue organisation, and on how these processes are altered in disease.<\/p>\n\n\n\n

She has held major scientific leadership positions in the UK, including Executive Chair of the Medical Research Council, and became Director of EMBO in 2022. She is a Fellow of the Royal Society and the Academy of Medical Sciences and an elected member of the US National Academy of Sciences.<\/p>\n\n\n\n

\n\n\n\n
\"\"<\/figure>
\n

PROF. ELAINE CHEW<\/strong><\/p>\n\n\n\n

“TBA”<\/p>\n\n\n\n

Professor of Engineering, King\u2019s College London; Founder and Director, Music Theranostics Laboratory<\/em>.<\/p>\n\n\n\n

September 9th 2027, 4PM (CEST)<\/p>\n<\/div><\/div>\n\n\n\n

Elaine Chew is a pianist, mathematician, and engineer whose interdisciplinary research connects music, mathematics, and cardiovascular science. A pioneer in music information research, she develops mathematical and computational approaches to understand musical structures and physiological signals.<\/p>\n\n\n\n

Her recent work explores the interactions between music and the cardiovascular system, including how music can be used to investigate cardiac rhythms and potentially inform personalised diagnostics and therapeutics. She is Professor of Engineering at King\u2019s College London and Founder and Director of its Music Theranostics Laboratory.<\/p>\n\n\n\n

\n\n\n\n
\"\"<\/figure>
\n

PROF. ALLAN BALMAIN<\/strong><\/p>\n\n\n\n

“TBA”<\/p>\n\n\n\n

Barbara Bass Bakar Distinguished Professor of Cancer Genetics, University of California San Francisco<\/em><\/p>\n\n\n\n

October 14th 2027, 4PM (CEST)<\/p>\n<\/div><\/div>\n\n\n\n

Allan Balmain is an internationally recognised cancer geneticist whose research has made major contributions to understanding the genetic and environmental factors that determine cancer susceptibility. His laboratory uses experimental genetics and systems approaches to investigate how inherited genetic variation interacts with environmental carcinogens to influence tumor development.<\/p>\n\n\n\n

His research has helped reveal the complex genetic architecture underlying cancer risk, progression, and response to environmental exposures. More recently, his work has focused on systems genetics and on understanding how carcinogens reshape mutational landscapes and gene expression programmes in normal and malignant tissues.<\/p>\n\n\n\n

\n\n\n\n
\"\"<\/figure>
\n

PROF. NAPOLEONE FERRARA<\/strong><\/p>\n\n\n\n

“TBA”<\/p>\n\n\n\n

Distinguished Professor of Pathology and Hildyard Endowed Chair in Eye Disease, University of California San Diego<\/em>.<\/p>\n\n\n\n

November 4th, 2027, 4PM (CET)<\/p>\n<\/div><\/div>\n\n\n\n

Napoleone Ferrara is a physician-scientist internationally renowned for his pioneering discoveries in angiogenesis. In 1989, he reported the isolation and cloning of vascular endothelial growth factor (VEGF) and subsequently established its central role in the formation of blood vessels in normal physiology and disease.<\/p>\n\n\n\n

His discoveries provided the scientific foundation for therapies targeting VEGF in cancer and retinal diseases, including the development of bevacizumab (Avastin). His research continues to investigate the molecular regulation of angiogenesis and its therapeutic implications in cancer and ophthalmological disease.<\/p>\n<\/div><\/div>\n\n\n\n

<\/div>\n\n\n\n

Certificate of attendance available upon request: info(at)cancerprev.com<\/p>\n\n\n\n

Subscribe to receive the online meeting links and to stay updated on upcoming seminars:<\/p>\n\n\n\n